Skip to main content


Log in

Intracavernous injections: Past, present, and future

  • Published:
Current Sexual Health Reports Aims and scope Submit manuscript


Intracavernous injection of vasoactive medications into the penis was the first available pharmacologic treatment developed to restore sexual function to men with erectile dysfunction. This paper relates this treatment’s history from the unique experience and perspective of the author, beginning in 1980 until now, using data involving nearly 7000 treated patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Virag R: Intracavernous injection of papaverine for erectile failure. Lancet 1982, 2:938.

    Article  PubMed  CAS  Google Scholar 

  2. Virag R: Intracavernous perfusion for diabetic impotence. Presented at the Second International Conference on Corpus Cavernosum Revascularization. Monaco; May 1980.

  3. Zorgniotti A, Lafleur W: Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985, 133:39–41.

    PubMed  CAS  Google Scholar 

  4. Brindley GS: Pilot experiments on the actions of drugs injected into the human corpus cavernosum. Br J Pharmacol 1986, 87:495–500.

    PubMed  CAS  Google Scholar 

  5. 1st World Meeting on Impotence records. Edited by Virag R. Les Editions du CERI; Paris; 1986.

  6. Virag R: Trial of intracavernous papaverine in the treatment of impotence [in French]. J Mal Vasc 1983, 8:293–295.

    PubMed  CAS  Google Scholar 

  7. Virag R, Shoukry K, Nollet F, Floresco J: Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 1991, 145:287–292.

    PubMed  CAS  Google Scholar 

  8. Bennett AH, Carpenter J, Barrada J: An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991, 146:1564–1565.

    PubMed  CAS  Google Scholar 

  9. Virag R, Adaikan PG: Effects of prostaglandin E1 on penile erection and erectile failure. J Urol 1987, 137:1010.

    PubMed  CAS  Google Scholar 

  10. Virag R: Les Injections Intracaverneuses. Paris: John Libbey-Eurotext; 2004.

    Google Scholar 

  11. Boolell M, Allen MJ, Ballard SA, et al.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996, 8:47–52.

    PubMed  CAS  Google Scholar 

  12. Virag R: Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urol 1999, 54:1073–1077.

    Article  PubMed  CAS  Google Scholar 

  13. Bachir D, Virag R, Galacteros F: Prevention and treatment of erectile disorders in sickle cell disease. Rev Med Interne 1997, 18(Suppl 1):46s–51s.

    Article  PubMed  Google Scholar 

  14. Virag R, Bachir D, Floresco J, Dufour B: Ambulatory treatment and prevention of priapism using alpha-agonists. Chirurgie 1997, 121:648–652.

    PubMed  CAS  Google Scholar 

  15. Melman A, Christ G: hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006, 17:1165–1176.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ronald Virag.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Virag, R. Intracavernous injections: Past, present, and future. Curr sex health rep 5, 168–170 (2008).

Download citation

  • Published:

  • Issue Date:

  • DOI: